Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.

Elexacaftor/Tezacaftor/Ivacaftor: A Bridge to Lung Retransplant in Cystic Fibrosis

This case report examines the potential role of the triple-combination cystic fibrosis transmembrane conductance regulator modulator elexacaftor/tezacaftor/ivacaftor in a patient with cystic fibrosis awaiting lung retransplant. The authors describe a 37-year-old male patient with chronic lung allograft dysfunction who experienced significant improvements in pulmonary function, sputum volume, and overall health after receiving the triple-combination therapy. While the therapy did not improve forced expiratory volume in 1 second, it led to a decrease in pulmonary exacerbations, improved pancreatic function, and reduced dependence on continuous antibiotic therapy. The case report highlights the potential benefits of this triple-combination therapy in improving quality of life for individuals with cystic fibrosis awaiting lung retransplant, while acknowledging the need for careful patient selection and monitoring.

Triple-Combination Therapy: A Potential Bridge to Retransplant

This case report showcases the potential benefits of the triple-combination cystic fibrosis transmembrane conductance regulator modulator elexacaftor/tezacaftor/ivacaftor in improving quality of life for individuals with cystic fibrosis awaiting lung retransplant. While the therapy did not improve forced expiratory volume in 1 second, it led to a decrease in pulmonary exacerbations, improved pancreatic function, and reduced dependence on continuous antibiotic therapy, suggesting it may be a valuable tool for bridging patients to retransplant.

Navigating the Desert of Cystic Fibrosis

Like a camel seeking a path through the desert, individuals with cystic fibrosis must navigate the challenges of this complex and debilitating disease. This case report offers a glimpse into the potential of triple-combination therapy in improving quality of life and potentially bridging patients to lung retransplant, providing a ray of hope for those facing the challenges of this condition.

Dr. Camel's Conclusion

This case report underscores the potential of triple-combination therapy as a valuable tool for bridging patients with cystic fibrosis to lung retransplant. While the therapy did not improve forced expiratory volume in 1 second, it led to significant improvements in other aspects of health and quality of life. This case highlights the need for careful patient selection and monitoring, but also suggests that triple-combination therapy may be a promising option for individuals facing the challenges of cystic fibrosis.